Sfoglia per Autore
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
2021 Rizzo A.; Ricci A.D.; Brandi G.
Bone targeting agents in patients with metastatic prostate cancer: State of the art
2021 Mollica V.; Rizzo A.; Rosellini M.; Marchetti A.; Ricci A.D.; Cimadamore A.; Scarpelli M.; Bonucci C.; Andrini E.; Errani C.; Santoni M.; Montironi R.; Massari F.
DNA damage response alterations in gastric cancer: Knocking down a new wall
2021 Ricci A.D.; Rizzo A.; Brandi G.
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
2021 Rizzo A.; Ricci A.D.; Brandi G.
First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges
2021 Rizzo A.; Ricci A.D.; Gadaleta-Caldarola G.; Brandi G.
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives
2021 Rizzo A.; Ricci A.D.; Brandi G.
Recent advances of immunotherapy for biliary tract cancer
2021 Rizzo A.; Ricci A.D.; Brandi G.
Radiofrequency ablation for intrahepatic cholangiocarcinoma: a tool upon the path of integrative modalities?
2021 Rizzo A.; Ricci A.D.; Gadaleta-Caldarola G.; Brandi G.
Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study
2022 Ricci A.D.; Pusceddu S.; Panzuto F.; Gelsomino F.; Massironi S.; De Angelis C.G.; Modica R.; Ricco G.; Torchio M.; Rinzivillo M.; Prinzi N.; Rizzi F.; Lamberti G.; Campana D.
Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma
2022 Rizzo A.; Ricci A.D.; Brandi G.
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials
2022 Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G.
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
2022 Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, Andrea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
2022 Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De Giglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco, Andrea Palloni, Giovanni Brandi.
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
2022 Di Federico A.; Mosca M.; Pagani R.; Carloni R.; Frega G.; De Giglio A.; Rizzo A.; Ricci D.; Tavolari S.; Di Marco M.; Palloni A.; Brandi G.
Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future
2022 Rizzo A.; Ricci A.D.; Cusmai A.; Acquafredda S.; De Palma G.; Brandi G.; Palmiotti G.
The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis
2022 Rizzo A.; Santoni M.; Mollica V.; Ricci A.D.; Calabro C.; Cusmai A.; Gadaleta-Caldarola G.; Palmiotti G.; Massari F.
Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data
2022 Ricci A.D.; Rizzo A.; Mollica V.; Schiavina R.; Fiorentino M.; Brunocilla E.; Ardizzoni A.; Massari F.
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: A meta-analysis
2022 Rizzo A.; Mollica V.; Santoni M.; Ricci A.D.; Gadaleta-Caldarola G.; Montironi R.; Massari F.
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?
2022 Rizzo A.; Dadduzio V.; Ricci A.D.; Massari F.; Di Federico A.; Gadaleta-Caldarola G.; Brandi G.
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
2023 Brandi G.; Deiana C.; Galvani L.; Palloni A.; Ricci A.D.; Rizzo A.; Tavolari S.
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile